Harver Group Targets Japanese Stem Cell Researchers
The Japanese biotech industry has boomed on the back of new legislation from the government. Harver Group is looking for profits from the JASDAQ; the Japanese version of the NASDAQ. They plan to take a position in an Index Fund on the JASDAQ.
View full press release